Optimi Health Completes Export of 1,000 5mg Psilocybin Capsules
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Optimi Health announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules. The shipment included 1,000 capsules of 5mg psilocybin, which are being prescribed in Australia for treatment-resistant depression, an indication for which regulated patient access is available.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPTH
Wall Street analysts forecast OPTH stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 4.870
Low
Averages
High
Current: 4.870
Low
Averages
High
No data
About OPTH
Optimi Health Corp. is a commercial-stage pharmaceutical company. The Company focuses on manufacturing and distributing good manufacturing practices (GMP) grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, the Company produces validated Methylenedioxymethamphetamine hydrochloride (MDMA) and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. It supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program. With its vertically integrated approach, the Company owns and operates two purpose-built 10,000-square-foot licensed production sites in Princeton, British Columbia and holds a Drug Establishment Licence (DEL), as issued by Health Canada.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Expands Medical Cannabis Platform with HelloMD Acquisition
- Tilray Acquires HelloMD: Tilray Brands strengthens its medical cannabis business by acquiring HelloMD, aiming to enhance patient access and education through a digital platform, which is expected to bolster its competitive position in the global medical cannabis market.
- Vireo Expands into Pennsylvania: Vireo Growth signs an agreement with Hive Holdings to acquire a retail license for approximately $20 million, allowing the establishment of up to six medical cannabis dispensaries in Pennsylvania, further expanding its footprint in the U.S. market.
- Optimi Health Export: Optimi Health completes its third commercial shipment of 1,000 capsules of 5mg psilocybin to Australia, reflecting growing demand for psychedelic treatments for treatment-resistant depression in the country.
- Helus Pharma Financials: Helus Pharma reports a fiscal year 2026 loss of $4.25 per share, widening from the previous year, yet its lead candidate HLP003 is progressing towards a pivotal Phase 3 trial, indicating ongoing investment potential in the biotech sector.
See More
Optimi Exports 5mg Psilocybin Capsules to Australia
- Export Achievement: Optimi successfully completed its latest export of 1,000 capsules of 5mg psilocybin to Australia, marking its third commercial shipment since the launch in September 2025, highlighting the company's ongoing progress in the treatment-resistant depression sector.
- Market Demand: These capsules are specifically designed for treatment-resistant depression, addressing a significant unmet medical need and underscoring the company's vital role in the global mental health treatment market.
- Regulatory Support: Australia became the first country to reschedule psilocybin as a controlled substance on July 1, 2023, allowing broader therapeutic use, which enhances Optimi's market access and sales potential.
- Production Capacity: All capsules are produced in-house at Optimi's GMP facility in British Columbia, Canada, ensuring product quality and compliance while generating recurring commercial revenue for the company.
See More
Optimi Exports 5mg Psilocybin Capsules to Australia
- Export Milestone: On June 29, 2026, Optimi completed its latest export of 1,000 capsules of 5mg psilocybin to Australia, marking its third commercial shipment since the launch in September 2025, indicating ongoing growth in the treatment of treatment-resistant depression (TRD).
- Market Demand: The capsules are prescribed for TRD, a condition that remains unresponsive after multiple standard antidepressant treatments, highlighting the drug's potential to meet significant medical needs and gain broader patient access under Australia's regulatory framework.
- Production Compliance: All capsules are produced in-house at Optimi's GMP facility in British Columbia, Canada, and shipped under export authorization from Health Canada, ensuring product quality and compliance, which further solidifies the company's position in the psychedelic drug market.
- Insurance Coverage Expansion: Optimi's psilocybin products are reimbursed by both public and private insurers in Australia, including the Department of Veterans' Affairs and the National Disability Insurance Scheme, with over 750 clinicians trained, demonstrating the company's proactive role in advancing the legalization and clinical application of psychedelics.
See More
Optimi Launches Microdose Psilocybin Products for Clinical Research
- New Product Launch: Optimi Health Corp. has introduced microdose psilocybin products at 1mg and 2mg, designed to provide consistent, validated doses for clinical research organizations, thereby enhancing the reliability and efficacy of studies.
- Meeting Market Demand: These new products expand Optimi's psilocybin range, particularly addressing the growing demand for low-dose psychedelics, especially the 5mg capsules currently prescribed for treatment-resistant depression in Australia.
- Full-Process Production: Optimi completes the entire production process from cultivation to packaging at its GMP facility in British Columbia, ensuring compliance with Health Canada's Drug Establishment License requirements, which enhances product quality and safety.
- International Market Supply: Optimi supplies products not only in Canada and Australia but also supports clinical research in international markets, indicating the company's strategic positioning and potential for market expansion in the global mental health treatment sector.
See More
Optimi Launches Microdose Psilocybin Products
- Product Launch: Optimi Health Corp. has announced the completion of production for its 1mg and 2mg microdose psilocybin products, providing clinical research organizations with consistent and validated doses required for controlled studies.
- Market Expansion: The new microdose formats extend Optimi's psilocybin product range, with the existing 5mg formulation already prescribed in Australia for treatment-resistant depression, highlighting the company's market potential in mental health therapies.
- Full-Scale Production: Optimi conducts the entire production process from cultivation to packaging at its GMP-compliant facility in British Columbia, ensuring product quality and supply chain control, which enhances the company's competitiveness in international markets.
- Clinical Research Support: The company is committed to supplying psilocybin products to qualified clinical research organizations, supporting patient access and clinical studies, thereby advancing the application prospects of psychedelics in mental health.
See More
Optimi Launches Microdose Psilocybin Products
- Product Innovation: Optimi Health Corp. has launched 1mg and 2mg microdose psilocybin products, providing research organizations with consistent and validated doses, thereby enhancing the reliability and efficacy of clinical studies.
- Market Expansion: The new products extend Optimi's psilocybin range, with an existing 5mg formulation already prescribed in Australia for treatment-resistant depression, indicating the company's market potential in mental health therapies.
- Production Capability: Optimi completes the entire production process from cultivation to packaging at its GMP facility in British Columbia, ensuring product quality meets Health Canada standards, which strengthens the company's competitiveness in international markets.
- Clinical Research Support: The company supplies these products to qualified clinical research organizations, supporting special access programs and clinical trials, further promoting the application and recognition of psychedelics in mental health treatment.
See More
Tilray Expands Medical Cannabis Platform with HelloMD Acquisition
- Tilray Acquires HelloMD: Tilray Brands strengthens its medical cannabis business by acquiring HelloMD, aiming to enhance patient access and education through a digital platform, which is expected to bolster its competitive position in the global medical cannabis market.
- Vireo Expands into Pennsylvania: Vireo Growth signs an agreement with Hive Holdings to acquire a retail license for approximately $20 million, allowing the establishment of up to six medical cannabis dispensaries in Pennsylvania, further expanding its footprint in the U.S. market.
- Optimi Health Export: Optimi Health completes its third commercial shipment of 1,000 capsules of 5mg psilocybin to Australia, reflecting growing demand for psychedelic treatments for treatment-resistant depression in the country.
- Helus Pharma Financials: Helus Pharma reports a fiscal year 2026 loss of $4.25 per share, widening from the previous year, yet its lead candidate HLP003 is progressing towards a pivotal Phase 3 trial, indicating ongoing investment potential in the biotech sector.
See More
Optimi Exports 5mg Psilocybin Capsules to Australia
- Export Achievement: Optimi successfully completed its latest export of 1,000 capsules of 5mg psilocybin to Australia, marking its third commercial shipment since the launch in September 2025, highlighting the company's ongoing progress in the treatment-resistant depression sector.
- Market Demand: These capsules are specifically designed for treatment-resistant depression, addressing a significant unmet medical need and underscoring the company's vital role in the global mental health treatment market.
- Regulatory Support: Australia became the first country to reschedule psilocybin as a controlled substance on July 1, 2023, allowing broader therapeutic use, which enhances Optimi's market access and sales potential.
- Production Capacity: All capsules are produced in-house at Optimi's GMP facility in British Columbia, Canada, ensuring product quality and compliance while generating recurring commercial revenue for the company.
See More
Optimi Exports 5mg Psilocybin Capsules to Australia
- Export Milestone: On June 29, 2026, Optimi completed its latest export of 1,000 capsules of 5mg psilocybin to Australia, marking its third commercial shipment since the launch in September 2025, indicating ongoing growth in the treatment of treatment-resistant depression (TRD).
- Market Demand: The capsules are prescribed for TRD, a condition that remains unresponsive after multiple standard antidepressant treatments, highlighting the drug's potential to meet significant medical needs and gain broader patient access under Australia's regulatory framework.
- Production Compliance: All capsules are produced in-house at Optimi's GMP facility in British Columbia, Canada, and shipped under export authorization from Health Canada, ensuring product quality and compliance, which further solidifies the company's position in the psychedelic drug market.
- Insurance Coverage Expansion: Optimi's psilocybin products are reimbursed by both public and private insurers in Australia, including the Department of Veterans' Affairs and the National Disability Insurance Scheme, with over 750 clinicians trained, demonstrating the company's proactive role in advancing the legalization and clinical application of psychedelics.
See More
Optimi Launches Microdose Psilocybin Products for Clinical Research
- New Product Launch: Optimi Health Corp. has introduced microdose psilocybin products at 1mg and 2mg, designed to provide consistent, validated doses for clinical research organizations, thereby enhancing the reliability and efficacy of studies.
- Meeting Market Demand: These new products expand Optimi's psilocybin range, particularly addressing the growing demand for low-dose psychedelics, especially the 5mg capsules currently prescribed for treatment-resistant depression in Australia.
- Full-Process Production: Optimi completes the entire production process from cultivation to packaging at its GMP facility in British Columbia, ensuring compliance with Health Canada's Drug Establishment License requirements, which enhances product quality and safety.
- International Market Supply: Optimi supplies products not only in Canada and Australia but also supports clinical research in international markets, indicating the company's strategic positioning and potential for market expansion in the global mental health treatment sector.
See More
Optimi Launches Microdose Psilocybin Products
- Product Launch: Optimi Health Corp. has announced the completion of production for its 1mg and 2mg microdose psilocybin products, providing clinical research organizations with consistent and validated doses required for controlled studies.
- Market Expansion: The new microdose formats extend Optimi's psilocybin product range, with the existing 5mg formulation already prescribed in Australia for treatment-resistant depression, highlighting the company's market potential in mental health therapies.
- Full-Scale Production: Optimi conducts the entire production process from cultivation to packaging at its GMP-compliant facility in British Columbia, ensuring product quality and supply chain control, which enhances the company's competitiveness in international markets.
- Clinical Research Support: The company is committed to supplying psilocybin products to qualified clinical research organizations, supporting patient access and clinical studies, thereby advancing the application prospects of psychedelics in mental health.
See More
Optimi Launches Microdose Psilocybin Products
- Product Innovation: Optimi Health Corp. has launched 1mg and 2mg microdose psilocybin products, providing research organizations with consistent and validated doses, thereby enhancing the reliability and efficacy of clinical studies.
- Market Expansion: The new products extend Optimi's psilocybin range, with an existing 5mg formulation already prescribed in Australia for treatment-resistant depression, indicating the company's market potential in mental health therapies.
- Production Capability: Optimi completes the entire production process from cultivation to packaging at its GMP facility in British Columbia, ensuring product quality meets Health Canada standards, which strengthens the company's competitiveness in international markets.
- Clinical Research Support: The company supplies these products to qualified clinical research organizations, supporting special access programs and clinical trials, further promoting the application and recognition of psychedelics in mental health treatment.
See More
